Overview
What Every Clinician Needs to Know About COVID-19 and Thrombosis
The Expert Circle
Click the "View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
As the COVID-19 pandemic continues to wage on, are you prepared to prevent and treat your patients for COVID-19-related venous thromboembolism (VTE)? In this short vlog, learn how to develop appropriate regimens with antithrombotic therapy for this patient population and hear about the promising PREVENT-HD trial. Leading VTE expert, Dr. Gregory Piazza, outlines key real-world insights that you need to know about these patients and their risk for VTE.
This activity is intended for clinical cardiologists, hospitalists, interventional cardiologists, internal medicine, primary care physicians, and vascular surgeons.
The purpose of this activity is to provide learners with an engaging, accessible vlog activity to help them better understand the pathophysiology with COVID-19 and thromboembolism, the latest recommendations for antithrombotic therapy in patients with COVID-19, and the most recent information on promising trials with COVID-19 and VTE prevention. Learners post-activity will be better able to ensure that this patient population receives optimal VTE prophylaxis to guarantee the best possible outcomes.
Upon completion of this activity, participants will be able to:
• Develop appropriate regimens with antithrombotic therapy for patients with COVID-19
• Outline key characteristics of the PREVENT-HD trial
• Develop appropriate regimens with antithrombotic therapy for patients with COVID-19
• Outline key characteristics of the PREVENT-HD trial
This activity is supported by an educational grant from Janssen Scientific Affairs, LLC.
This activity was part of a serial learning curriculum. This functionality is no longer available due to activity expiration.
Gregory Piazza, MD, MS
Director, Vascular Medicine Section, Division of Cardiovascular Medicine
Brigham and Women's Hospital
Boston, MA
Director, Vascular Medicine Section, Division of Cardiovascular Medicine
Brigham and Women's Hospital
Boston, MA
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Gregory Piazza, MD, MS
Grant/Research Support: Amgen, Bayer, BMS/Pfizer Alliance, Boston Scientific Corporation, Janssen, Portola
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Rivaroxaban for non-hospitalized patients with COVID-19; fondaparinux as VTE prevention in noncritically ill patients with COVID-19; postdischarge VTE prophylaxis with LMWH in hospitalized patients with COVID-19
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 15 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
